Abstract
Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity of PLD is hand–foot syndrome. Unlike free doxorubicin, PLD is unlikely to cause alopecia, nausea, myelosuppression, or cardiotoxicity. Additionally, no premedications are required. We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progressive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs.
This is a preview of subscription content, log in via an institution to check access.
Availability of data and materials
Not applicable.
References
Alberts DS et al (2004) Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31(6 Suppl 13):53–90
Gabizon A et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987–992
Northfelt DW et al (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 36(1):55–63
Skubitz KM et al (2017) Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol 80(4):787–798
Savani M, Murugan P, Skubitz KM (2019) Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure. Clin Sarcoma Res 9:1
Skubitz KM, Skubitz AP (1998) Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 9(1):45–50
Cannon TL et al (2012) Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? Oncologist 17(12):1541–1546
Matsuo K et al (2012) Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer. Oncologist 17(12):1598–1599
Pease DF et al (2019) Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity. Cancer Chemother Pharmacol 84(1):217–221
Meng L et al (2020) Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 85(1):3–7
Carron PL, Padilla M, Maurizi Balzan J (2014) Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment. Hemodial Int 18(4):846–847
Kwa M et al (2012) Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 17(12):1534–1540
Yemm KE et al (2019) Renal toxicity with liposomal doxorubicin in metastatic breast cancer. J Oncol Pharm Pract 25(7):1738–1742
Naranjo CA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245
Jhaveri KD et al (2013) Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int 84(1):34–44
Mohamed N et al (2013) Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 61(5):778–781
Guo J et al (2008) RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 19(5):961–972
Gabizon A, Meshorer A, Barenholz Y (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77(2):459–469
Gabizon A (2003) Emerging role of liposomal drug carrier systems in cancer chemotherapy. J Liposome Res 13(1):17–20
La-Beck NM et al (2012) Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69(1):43–50
Li Y et al (2007) Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol 106(2):375–380
Acknowledgements
The authors thank Michael Franklin for editorial assistance.
Funding
We thank the James Dinerstein and Kevin Franklin families for research support. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Conception and design: KMS; manuscript writing MS and KMS; final approval: all authors; pathological examination LB, MB, and KW; patient’s management: KMS and KW. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest in preparing this article.
Ethics approval and consent to participate
Not applicable, although consent to publish was obtained.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Savani, M., Woerner, K., Bu, L. et al. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review. Cancer Chemother Pharmacol 87, 289–294 (2021). https://doi.org/10.1007/s00280-020-04203-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-020-04203-z